Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening

Zhi Hong Yu, Lan Chen, Li Wu, Sijiu Liu, Lina Wang, Zhong-Yin Zhang

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

SHP2, encoded by PTPN11, is a non-receptor protein tyrosine phosphatase (PTP) containing two tandem Src homology-2 (SH2) domains. It is expressed ubiquitously and plays critical roles in growth factor mediated processes, primarily by promoting the activation of the RAS/ERK signaling pathway. Genetic and biochemical studies have identified SHP2 as the first bona fide oncoprotein in the PTP superfamily, and a promising target for anti-cancer and anti-leukemia therapy. Here, we report a structure-based approach to identify SHP2 inhibitors with a novel scaffold. Through sequential virtual screenings and in vitro inhibition assays, a reversible competitive SHP2 inhibitor (C21) was identified. C21 is structurally distinct from all known SHP2 inhibitors. Combining molecular dynamics simulation and binding free energy calculation, a most likely binding mode of C21 with SHP2 is proposed, and further validated by site-directed mutagenesis and structure-activity relationship studies. This binding mode is consistent with the observed potency and specificity of C21, and reveals the molecular determinants for further optimization based on the new scaffold.

Original languageEnglish
Pages (from-to)4238-4242
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume21
Issue number14
DOIs
StatePublished - Jul 15 2011

Fingerprint

Non-Receptor Protein Tyrosine Phosphatases
Non-Receptor Type 11 Protein Tyrosine Phosphatase
Protein Tyrosine Phosphatases
src Homology Domains
MAP Kinase Signaling System
Oncogene Proteins
Molecular Dynamics Simulation
Structure-Activity Relationship
Site-Directed Mutagenesis
Phosphoric Monoester Hydrolases
Scaffolds
Tyrosine
Molecular Biology
Intercellular Signaling Peptides and Proteins
Screening
Leukemia
Mutagenesis
Molecules
Free energy
Molecular dynamics

Keywords

  • Drug discovery
  • Molecular dynamics simulation
  • Protein tyrosine phosphatase (PTP)
  • SHP2 inhibitor
  • Virtual screening

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening. / Yu, Zhi Hong; Chen, Lan; Wu, Li; Liu, Sijiu; Wang, Lina; Zhang, Zhong-Yin.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 21, No. 14, 15.07.2011, p. 4238-4242.

Research output: Contribution to journalArticle

Yu, Zhi Hong ; Chen, Lan ; Wu, Li ; Liu, Sijiu ; Wang, Lina ; Zhang, Zhong-Yin. / Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening. In: Bioorganic and Medicinal Chemistry Letters. 2011 ; Vol. 21, No. 14. pp. 4238-4242.
@article{86d4f5f322ed4aedb2e62ac86997ef7e,
title = "Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening",
abstract = "SHP2, encoded by PTPN11, is a non-receptor protein tyrosine phosphatase (PTP) containing two tandem Src homology-2 (SH2) domains. It is expressed ubiquitously and plays critical roles in growth factor mediated processes, primarily by promoting the activation of the RAS/ERK signaling pathway. Genetic and biochemical studies have identified SHP2 as the first bona fide oncoprotein in the PTP superfamily, and a promising target for anti-cancer and anti-leukemia therapy. Here, we report a structure-based approach to identify SHP2 inhibitors with a novel scaffold. Through sequential virtual screenings and in vitro inhibition assays, a reversible competitive SHP2 inhibitor (C21) was identified. C21 is structurally distinct from all known SHP2 inhibitors. Combining molecular dynamics simulation and binding free energy calculation, a most likely binding mode of C21 with SHP2 is proposed, and further validated by site-directed mutagenesis and structure-activity relationship studies. This binding mode is consistent with the observed potency and specificity of C21, and reveals the molecular determinants for further optimization based on the new scaffold.",
keywords = "Drug discovery, Molecular dynamics simulation, Protein tyrosine phosphatase (PTP), SHP2 inhibitor, Virtual screening",
author = "Yu, {Zhi Hong} and Lan Chen and Li Wu and Sijiu Liu and Lina Wang and Zhong-Yin Zhang",
year = "2011",
month = "7",
day = "15",
doi = "10.1016/j.bmcl.2011.05.078",
language = "English",
volume = "21",
pages = "4238--4242",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "14",

}

TY - JOUR

T1 - Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening

AU - Yu, Zhi Hong

AU - Chen, Lan

AU - Wu, Li

AU - Liu, Sijiu

AU - Wang, Lina

AU - Zhang, Zhong-Yin

PY - 2011/7/15

Y1 - 2011/7/15

N2 - SHP2, encoded by PTPN11, is a non-receptor protein tyrosine phosphatase (PTP) containing two tandem Src homology-2 (SH2) domains. It is expressed ubiquitously and plays critical roles in growth factor mediated processes, primarily by promoting the activation of the RAS/ERK signaling pathway. Genetic and biochemical studies have identified SHP2 as the first bona fide oncoprotein in the PTP superfamily, and a promising target for anti-cancer and anti-leukemia therapy. Here, we report a structure-based approach to identify SHP2 inhibitors with a novel scaffold. Through sequential virtual screenings and in vitro inhibition assays, a reversible competitive SHP2 inhibitor (C21) was identified. C21 is structurally distinct from all known SHP2 inhibitors. Combining molecular dynamics simulation and binding free energy calculation, a most likely binding mode of C21 with SHP2 is proposed, and further validated by site-directed mutagenesis and structure-activity relationship studies. This binding mode is consistent with the observed potency and specificity of C21, and reveals the molecular determinants for further optimization based on the new scaffold.

AB - SHP2, encoded by PTPN11, is a non-receptor protein tyrosine phosphatase (PTP) containing two tandem Src homology-2 (SH2) domains. It is expressed ubiquitously and plays critical roles in growth factor mediated processes, primarily by promoting the activation of the RAS/ERK signaling pathway. Genetic and biochemical studies have identified SHP2 as the first bona fide oncoprotein in the PTP superfamily, and a promising target for anti-cancer and anti-leukemia therapy. Here, we report a structure-based approach to identify SHP2 inhibitors with a novel scaffold. Through sequential virtual screenings and in vitro inhibition assays, a reversible competitive SHP2 inhibitor (C21) was identified. C21 is structurally distinct from all known SHP2 inhibitors. Combining molecular dynamics simulation and binding free energy calculation, a most likely binding mode of C21 with SHP2 is proposed, and further validated by site-directed mutagenesis and structure-activity relationship studies. This binding mode is consistent with the observed potency and specificity of C21, and reveals the molecular determinants for further optimization based on the new scaffold.

KW - Drug discovery

KW - Molecular dynamics simulation

KW - Protein tyrosine phosphatase (PTP)

KW - SHP2 inhibitor

KW - Virtual screening

UR - http://www.scopus.com/inward/record.url?scp=79959910681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959910681&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2011.05.078

DO - 10.1016/j.bmcl.2011.05.078

M3 - Article

C2 - 21669525

AN - SCOPUS:79959910681

VL - 21

SP - 4238

EP - 4242

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 14

ER -